Procept Biorobotics at Jefferies Conference: Strategic Innovations in BPH Treatment

Procept Biorobotics (PRCT) presented at the Jefferies Global Healthcare Conference, outlining its strategy to revolutionize BPH treatment and become a global leader in urology, targeting a commercial product for early-stage prostate cancer by early 2028. The company aims to capture 20% of the U.S. resective surgical market by completing approximately 52,000 procedures in 2025 and reported a 5% year-over-year growth in Q1 2024 utilization, expressing confidence in achieving over 20% growth by the end of 2025. Procept addressed potential challenges related to physician fee cuts and competitive pressures, affirming minimal expected impact and highlighting the advantages of aquablation over alternative treatments.

Analysis

Procept Biorobotics (NASDAQ:PRCT) detailed a robust strategic vision at the Jefferies Global Healthcare Conference, centered on revolutionizing benign prostatic hyperplasia (BPH) treatment and expanding into the early-stage prostate cancer market. The company projects completing approximately 52,000 BPH procedures by 2025, aiming to secure a 20% share of the U.S. resective surgical market. Financially, Procept reported a 5% year-over-year increase in Q1 2024 utilization and expressed high confidence in achieving over 20% utilization growth by the end of 2025, despite reiterating what it terms conservative handpiece guidance. In Q1, 43 systems were sold at an average selling price (ASP) of $435,000, with full-year ASP guidance between $430,000 and $440,000. Management addressed key investor concerns, stating that the upcoming Category 1 reimbursement code implementation is not expected to negatively impact the business, with the crucial facility payment for aquablation remaining competitive at APC level 6 (approximately $9,300). While acknowledging potential physician fee adjustments, the company believes the impact will be minimal, as ~50% of its surgeons are salaried and the focus remains on relative value compared to other procedures. Competitive pressures, including from prostate artery embolization (PAE), were downplayed, citing aquablation's superior efficacy and lower retreatment rates. Tariff impacts, initially projected at $5 million, have been revised down to $1-2 million due to de-escalation, with ongoing mitigation strategies like inventory management and potential supply chain adjustments expected to protect profitability and gross margin expansion. The saline shortage issue from Q4 2024 was confirmed resolved as of Q2 2025. Looking ahead, Procept is advancing its Water four study for prostate cancer, with enrollment targeted for completion between mid-2026 and end-2026, and a commercial launch anticipated in the first half of 2028. The company received positive signals from the FDA, including Breakthrough Device Designation and the removal of a contraindication, supporting its strategy to offer a safe alternative to radical treatments for early-stage prostate cancer by targeting a market of men currently under active surveillance. The overall sentiment from the presentation appears extremely positive, buoyed by these strategic advancements and operational updates.

Key Decisions for Investors

• Investors should monitor Procept's ability to meet its 2025 procedure volume target of 52,000 and achieve the projected over 20% utilization growth, as these are key indicators of market penetration and commercial traction.
• Careful attention should be paid to the final details and impact of the Category 1 code implementation in January 2026, particularly on physician reimbursement, despite management's current confidence in minimal adverse effects.
• The progression of the Water four study and subsequent milestones for the early-stage prostate cancer product represent significant long-term value drivers; trial enrollment pace and interim data releases warrant close observation.
• Evaluate the effectiveness of tariff mitigation strategies on gross margins and EBITDA, especially given the revised lower impact and the company's commitment to offset increased costs.
• Consider the company's conservative guidance as a potential source of upside, particularly if underlying business trends and system placements (target of ~210 for the year) continue to outperform internal expectations.